InvestorsObserver
×
News Home

Analyst Rating: Will Esperion Therapeutics Inc (ESPR) Stock Outperform the Market?

Monday, March 20, 2023 10:40 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will Esperion Therapeutics Inc (ESPR) Stock Outperform the Market?

InvestorsObserver is giving Esperion Therapeutics Inc (ESPR) an Analyst Rating Rank of 24, meaning ESPR is ranked higher by analysts than 24% of stocks. The average price target for ESPR is $11.555 and analyst’s rate the stock as a Buy.

Overall Score - 3.6
Wall Street analysts are rating ESPR a Buy today. Find out what this means to you and get the rest of the rankings on ESPR!

Why are Analyst Ratings Important?

Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected. InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.

What's Happening With Esperion Therapeutics Inc Stock Today?

Esperion Therapeutics Inc (ESPR) stock is trading at $1.62 as of 10:40 AM on Monday, Mar 20, an increase of $0.07, or 4.19% from the previous closing price of $1.55. The stock has traded between $1.46 and $1.63 so far today. Volume today is light. So far 2,548,354 shares have traded compared to average volume of 5,365,384 shares. Click Here to get the full Stock Report for Esperion Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App